Aim: Elevated levels of LDL and triglycerides, along with low levels of HDL, are key contributors to cardiovascular disease. If the increase of harmful fats is prevented, it will be a great step towards the prevention of diseases. The two drugs atorvastatin and rosuvastatin are the most commonly used drugs to reduce LDL and triglycerides and increase HDL in patients. The present study aimed to compare the effectiveness of Rosuvastatin and Atorvastatin on changes in LDL, TG and HDL using a systematic review and meta-analysis method.
Materials and methods: The present study was conducted on the basis of the protocol of systematic review and meta-analyses. The ISI, Cochrane Library, Google Scholar, PubMed, Scopus, and Elsevier databases were independently searched by two researchers using Mesh keywords in different regions of the world during 2003 to 2025. Data was analyzed using the STATA software.
Key findings: Effectiveness of Atorvastatin on the reduction of LDL was 51.49 mg/dl (42.75-60.23 %, CI =95 %) versus Rosuvastatin with a reduction of 55.66 mg/dl (46.32-65 and CI =95 %). The effectiveness of Atorvastatin on the rise of HDL was 1.85 mg/dl (-3.23-0.46 and CI =95 %) versus Rosuvastatin with a rise of 3.87 mg/dl (2.08-5.66 and CI =95 %); and the effectiveness of atorvastatin on the reduction of TG was 24.76 mg/dl (18.14-31.88 and CI = 95 %) versus the effectiveness of Rosuvastatin with a reduction of 31.98 mg/dl (24. 41-39.55 and CI = 95 %).
Significance: According to research results, Rosuvastatin was better than Atorvastatin and decreased triglyceride and LDL and increased HDL in all cases.
Keywords: Atorvastatin; High-density lipoprotein (HDL); Low-density lipoprotein (LDL); Rosuvastatin; Triglyceride (TG).
Copyright © 2025 Elsevier Inc. All rights reserved.